Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Share Price

Equities

300534

CNE100002CP5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 03:30:00 30/04/2024 am IST 5-day change 1st Jan Change
8.23 CNY +0.98% Intraday chart for Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD +3.26% -16.62%

Financials

Sales 2022 413M 57.07M 4.76B Sales 2023 1.08B 149M 12.44B Capitalization 2.99B 414M 34.5B
Net income 2022 25M 3.45M 288M Net income 2023 61M 8.42M 703M EV / Sales 2022 6.27 x
Net cash position 2022 97.83M 13.51M 1.13B Net cash position 2023 144M 19.94M 1.66B EV / Sales 2023 2.64 x
P/E ratio 2022
104 x
P/E ratio 2023
48.6 x
Employees 763
Yield 2022 *
-
Yield 2023
0.2%
Free-Float 59.9%
More Fundamentals * Assessed data
Dynamic Chart
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Proposes Final Cash Dividend for 2023 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD cancelled the transaction announced on July 17, 2023 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Longshenrongfa Pharmaceutical Renews Food Production License MT
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD announced that it expects to receive CNY 485.796067 million in funding from Gansu Pharmaceutical Investment Group Co., Ltd., Gansu Great Wall Xinglong Silk Road Fund Management Co., Ltd. and other investors. CI
An unknown buyer agreed to acquire 7.1% stake in Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD for CNY 234.5 million. CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chinese Shares Rebound; Longshenrongfa Pharma Rises 3.9% on Renewal of Drug Production License MT
Gansu Longshenrongfa Pharma Renews Drug Production License MT
Drug Regulator Approves Changes to Longshenrongfa Pharma's Drug Production License MT
Longshenrongfa Pharma Gets Nod for Proposed Changes in License MT
More news
1 day+0.98%
1 week+3.26%
1 month-2.83%
3 months+11.07%
6 months-15.85%
Current year-16.62%
More quotes
1 week
8.00
Extreme 8
8.28
1 month
7.09
Extreme 7.09
8.52
Current year
6.30
Extreme 6.3
11.90
1 year
6.30
Extreme 6.3
12.36
3 years
5.24
Extreme 5.24
17.50
5 years
4.76
Extreme 4.76
17.50
10 years
4.76
Extreme 4.76
31.56
More quotes
Managers TitleAgeSince
Chief Executive Officer 39 10/23/10
Director of Finance/CFO 37 01/09/01
Director/Board Member 48 03/02/03
Members of the board TitleAgeSince
Director/Board Member 49 29/12/29
Director/Board Member 54 30/20/30
Director/Board Member 48 10/17/10
More insiders
Date Price Change Volume
30/24/30 8.23 +0.98% 7,340,000
29/24/29 8.15 +2.26% 7,332,200
26/24/26 7.97 +0.89% 6,497,700
25/24/25 7.9 +0.51% 5,819,400

End-of-day quote Shenzhen S.E., April 30, 2024

More quotes
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd is a company mainly engaged in research and development, production and sales of Chinese traditional medicine. The Company operates two segments. The Pharmaceutical Manufacturing segments is involved in the production and sale of Chinese traditional medicine, health food and raw materials. Its primary product is Yuanhuzhitong dripping pills, which is used for the treatment of stomach pain, rib pain and headache. The Company also produces other drugs, including compound salvia miltiorrhiza tablets, anti-inflammatory and gallbladder tablets, as well as Sanqi injury tablets. The Sales and Logistics segment operates logistics and distribution business.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300534 Stock